Pharmaceuticals News and Research

RSS

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

Denator's heat-stabilization system preserves lipids at close-to-in vivo-levels

Denator AB announced today that the company’s heat-stabilization system has been demonstrated to preserve lipids at close-to-in vivo-levels. To preserve lipids in a reliable manner prior to mass spectrometry-based analysis is pivotal to accurately quantify and identify potential biomarkers and perform disease research.

19 Mar 2015

Austrian Centre of Industrial Biotechnology develops method to reduce production costs of valuable drugs

Imagine a loved relative suffering from cancer - and you could not afford a treatment because the drugs are too expensive. The Austrian Centre of Industrial Biotechnology (acib) developed a method with the power to reduce production costs of highly valued drugs significantly.

19 Mar 2015

Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Columbia Laboratories, Inc., today announced financial results for the three- and twelve-month periods ended December 31, 2014.

18 Mar 2015

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH).

18 Mar 2015

New radiation treatment for brain cancer implanted in first human being at CTRC

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor.

18 Mar 2015

Researchers discover new metabolic mechanisms linked to macrophage polarization

A group of researchers from Washington University in St. Louis, Agios Pharmaceuticals and ITMO University has discovered new metabolic mechanisms that regulate macrophage polarization - the unique ability of these immune cells to change their specialization depending on the required task.

18 Mar 2015

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.

18 Mar 2015

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

Pharmalink AB, a specialty pharma company, announces that it has acquired a novel product candidate in development for treating inflammation from Synartro AB. No financial details are disclosed.

18 Mar 2015

New study finds that prices of leading cancer drugs increased by 10% annually since 1995

The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist -- but the exact reasons for the cost increases are unclear.

18 Mar 2015

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients’ needs and concerns.

17 Mar 2015

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise.

17 Mar 2015

Janssen Pharmaceutical to invest $10 million in global Dementia Discovery Fund

Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global dementia discovery fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer's disease.

17 Mar 2015

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide.

16 Mar 2015

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.

16 Mar 2015

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04.

16 Mar 2015

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Inc., a biopharmaceutical company, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company, announced today that on March 13, 2015, they have entered into a definitive merger agreement.

16 Mar 2015

Potential solutions to help reduce high cost of cancer drugs in the U.S.

Increasingly high prices for cancer drugs are affecting patient care in the U.S. and the American health care system overall, say the authors of a special article published online in the journal Mayo Clinic Proceedings.

16 Mar 2015

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2014 and provided a corporate update.

13 Mar 2015

Par Pharmaceutical files registration statement with SEC for initial public offering of common stock

Par Pharmaceutical Holdings, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

13 Mar 2015

Pharmaceuticals News and Research

Janssen announces acquisition of XO1

Denator's heat-stabilization system preserves lipids at close-to-in vivo-levels

Austrian Centre of Industrial Biotechnology develops method to reduce production costs of valuable drugs

Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

New radiation treatment for brain cancer implanted in first human being at CTRC

Researchers discover new metabolic mechanisms linked to macrophage polarization

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

New study finds that prices of leading cancer drugs increased by 10% annually since 1995

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Janssen Pharmaceutical to invest $10 million in global Dementia Discovery Fund

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

Ruthigen, Pulmatrix sign definitive merger agreement

Potential solutions to help reduce high cost of cancer drugs in the U.S.

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

Par Pharmaceutical files registration statement with SEC for initial public offering of common stock

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring